Shionogi & Co., Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SH0.F | 4574.T | 000999.SZ | SHUKRAPHAR.BO | 2005.HK | 9273.T | |
|---|---|---|---|---|---|---|
| Market cap | 14.58B | 13.38B | 43.15B | 35.36B | 7.63B | 35.46B |
| P/E (TTM) | 11.1 | 19.4 | 13.4 | 102.4 | 14.7 | 9.5 |
| Forward P/E | 5.5 | 57.8 | 11.7 | — | 10.6 | 10.1 |
| Price/book | 1.5 | 1.6 | 1.9 | 38.2 | 1.0 | 1.1 |
| Dividend yield | 3.17% | 1.33% | 3.92% | 0.01% | 3.24% | 2.15% |
| 1-year change | +16.35% | −4.71% | −11.05% | +99.05% | −15.48% | +5.42% |
| Today | −4.89% | +1.14% | +1.01% | +0.08% | +1.34% | +0.60% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All SH0.F news ›Shionogi wins quantum drug-design prize with D-Wave’s help
Ivy Delaney has been working with neural networks and machine learning since the mid-nineties, back when a couple of hidden layers and a long afternoon of training counted as ambitious. She has watched the field go from academic curiosity…
Shionogi Wins NEDO Award for Quantum-Assisted Drug Discovery
Insider Brief PRESS RELEASE — D-Wave Quantum Inc. (NASDAQ: QBTS) (“D-Wave“), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, today announced that its customer…
Shionogi to Present New Real-World Data Advancing the Understanding of ALS at the 2026 Annual NEALS Meeting
Data being presented at the 2026 Annual NEALS Meeting include analyses evaluating the association of RADICAVA ORS treatment with progression-free survival and functional outcomes in patients with ALS. Additional research explores the role…
F2G and Shionogi Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome® Followed by Standard of Care in Invasive Aspergillosis in Late-Breaking Oral Presentation at IDWeek 2026
These data will be submitted to regulatory authorities in the U.S. by F2G and in Europe and Asia by Shionogi. F2G anticipates resubmitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2026.…
Shionogi and F2G report Phase 3 results for oral antifungal olorofim
October 22, 2026 | Thursday | News Shionogi and F2G have reported detailed results from the global Phase 3 OASIS study evaluating investigational oral antifungal olorofim against AmBisome, followed by standard of care, in adults with…
IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections
Rapid Fire session will feature new data from the SENTRY Global Antimicrobial Surveillance Program demonstrating potent in vitro activity of cefiderocol against Pseudomonas aeruginosa in ventilator-associated pneumonia (VAP) New systematic…
Shionogi and F2G’s invasive aspergillosis drug shows long-term benefit
Patients treated with Shionogi & F2G’s invasive aspergillosis drug were released from hospital sooner than those in the comparator arm. Shionogi and F2G are releasing further data from a non-inferiority study of the latter’s oral invasive…
Analyzing Sonoma Pharmaceuticals (NASDAQ:SNOA) & Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)
Posted by Defense World Staff on Oct 19th, 2026 Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) are both healthcare companies, but which is the better…
Bacterial Infectious Diseases Therapeutics Market Gains Momentum as Shionogi Secures US$482 Million U.S. Government Contract for Drug-Resistant Infections
The bacterial infectious diseases therapeutics market is gaining strategic importance as pharmaceutical companies and governments expand efforts to address antibiotic resistance and difficult to treat bacterial infections On August 28 2026…
Japan’s Shionogi acquires America’s IntraBio in USD2bn deal
Cleary Gottlieb Steen & Hamilton, DLA Piper and Kirkland & Ellis have advised on Shionogi’s USD2 billion acquisition of IntraBio, strengthening its rare disease portfolio with AQNEURSA and specialist expertise. Under the agreement signed…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- biospace.com2
- law360.com2
- nippon.com2
- thepharmaletter.com2
- biopharmadive.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 23 articles, not a forecast.